(ASPI) ASP Isotopes Common Stock - Ratings and Ratios
Uranium, Lithium, Molybdenum, Silicon, Carbon
Description: ASPI ASP Isotopes Common Stock
ASP Isotopes Inc. is a development-stage advanced materials company that specializes in producing and commercializing isotopes used in various high-tech industries, including nuclear medicine, semiconductors, and energy. The companys business is divided into two main segments: Nuclear Fuels and Specialist Isotopes and Related Services. The Nuclear Fuels segment is focused on developing technologies for producing high-assay low-enriched uranium (HALEU) and Lithium-6, which are crucial for advanced nuclear fuels.
The companys Specialist Isotopes and Related Services segment is involved in separating and commercializing high-value, low-volume isotopes such as C-14, Mo-100, and Si-28, which are used in pharmaceuticals, agrochemicals, nuclear medical imaging, and semiconductors. ASP Isotopes Inc. leverages its proprietary Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE) technologies to separate gas species and isotopes. These technologies enable the company to produce a range of isotopes, including Molybdenum-100, Silicon-28, and Carbon-14, which are in high demand across various industries.
Given the current market trends and the companys financials, ASP Isotopes Inc. is poised for significant growth. The companys focus on developing innovative technologies for isotope separation positions it well in the growing market for advanced nuclear fuels and high-tech isotopes. With a market capitalization of $655.07M USD and a forward P/E ratio of 54.35, the stock is expected to experience volatility. However, the long-term outlook appears promising, driven by the increasing demand for isotopes in the nuclear medical industry, semiconductors, and the energy sector.
Analyzing the technical data, the stocks current price is $7.69, with a 20-day SMA of $8.14 and a 50-day SMA of $6.96, indicating a potential bullish crossover. The 200-day SMA is $5.37, suggesting a strong uptrend. The ATR of 0.76 (9.92% of the current price) indicates moderate volatility. Considering the fundamental data, the lack of a P/E ratio due to negative earnings is not uncommon for development-stage companies. The forward P/E of 54.35 suggests that investors are pricing in significant future growth. Based on these factors, a forecast for ASPI could involve a potential short-term correction due to the current SMA20 and SMA50 crossover, followed by a continuation of the long-term uptrend driven by the companys innovative technologies and growing demand for its products.
In the next 6-12 months, ASP Isotopes Inc.s stock price could be influenced by its ability to advance its technologies, secure new contracts, and expand its production capabilities. If the company makes significant progress in these areas, it could drive the stock price towards the 52-week high of $9.62. Conversely, failure to meet expectations could result in a decline towards the 52-week low of $2.03. Investors should closely monitor the companys announcements and industry trends to make informed decisions.
ASPI Stock Overview
| Market Cap in USD | 859m |
| Sub-Industry | Diversified Metals & Mining |
| IPO / Inception | 2022-11-10 |
ASPI Stock Ratings
| Growth Rating | 82.5% |
| Fundamental | 37.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 241% |
| Analyst Rating | 5.0 of 5 |
ASPI Dividends
Currently no dividends paidASPI Growth Ratios
| Growth Correlation 3m | 62.2% |
| Growth Correlation 12m | 73.2% |
| Growth Correlation 5y | 86.5% |
| CAGR 5y | 56.49% |
| CAGR/Max DD 5y | 0.64 |
| Sharpe Ratio 12m | 0.98 |
| Alpha | 268.01 |
| Beta | 2.175 |
| Volatility | 98.95% |
| Current Volume | 8997.2k |
| Average Volume 20d | 4135.8k |
| Stop Loss | 8.6 (-7.3%) |
| Signal | -2.38 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-100.0m TTM) > 0 and > 6% of Revenue (6% = 274.9k TTM) |
| FCFTA -0.21 (>2.0%) and ΔFCFTA -6.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 2067 % (prev 1048 %; Δ 1019 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.14 (>3.0%) and CFO -19.7m > Net Income -100.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 14.72 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (73.0m) change vs 12m ago 48.59% (target <= -2.0% for YES) |
| Gross Margin 39.26% (prev 44.82%; Δ -5.56pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 4.81% (prev 4.19%; Δ 0.61pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -289.0 (EBITDA TTM -98.8m / Interest Expense TTM 345.0k) >= 6 (WARN >= 3) |
Altman Z'' -7.16
| (A) 0.70 = (Total Current Assets 101.6m - Total Current Liabilities 6.90m) / Total Assets 135.9m |
| (B) -1.03 = Retained Earnings (Balance) -139.7m / Total Assets 135.9m |
| warn (B) unusual magnitude: -1.03 — check mapping/units |
| (C) -1.05 = EBIT TTM -99.7m / Avg Total Assets 95.3m |
| (D) -1.29 = Book Value of Equity -138.8m / Total Liabilities 107.6m |
| Total Rating: -7.16 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 37.14
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -3.15% = -1.57 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 3.98 = -2.01 |
| 5. Debt/Ebitda -1.02 = -2.50 |
| 7. RoE -259.1% = -2.50 |
| 8. Rev. Trend 93.07% = 4.65 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend -57.31% = -1.43 |
| 11. EPS CAGR -180.2% = -2.50 |
What is the price of ASPI shares?
Over the past week, the price has changed by -0.70%, over one month by -0.75%, over three months by +21.31% and over the past year by +299.14%.
Is ASP Isotopes Common Stock a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ASPI is around 10.37 USD . This means that ASPI is currently undervalued and has a potential upside of +11.75% (Margin of Safety).
Is ASPI a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ASPI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11 | 18.5% |
| Analysts Target Price | 11 | 18.5% |
| ValueRay Target Price | 12 | 29.1% |
Last update: 2025-08-25 04:31
ASPI Fundamental Data Overview
CCE Cash And Equivalents = 67.7m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 54.3478
P/S = 187.4765
P/B = 34.0413
Beta = 3.388
Revenue TTM = 4.58m USD
EBIT TTM = -99.7m USD
EBITDA TTM = -98.8m USD
Long Term Debt = 99.5m USD (from longTermDebt, last quarter)
Short Term Debt = 988.9k USD (from shortTermDebt, last quarter)
Debt = 100.5m USD (Calculated: Short Term 988.9k + Long Term 99.5m)
Net Debt = 34.0m USD (from netDebt column, last quarter)
Enterprise Value = 891.8m USD (858.9m + Debt 100.5m - CCE 67.7m)
Interest Coverage Ratio = -289.0 (Ebit TTM -99.7m / Interest Expense TTM 345.0k)
FCF Yield = -3.15% (FCF TTM -28.1m / Enterprise Value 891.8m)
FCF Margin = -612.6% (FCF TTM -28.1m / Revenue TTM 4.58m)
Net Margin = -2182 % (Net Income TTM -100.0m / Revenue TTM 4.58m)
Gross Margin = 39.26% ((Revenue TTM 4.58m - Cost of Revenue TTM 2.78m) / Revenue TTM)
Tobins Q-Ratio = -6.42 (set to none) (Enterprise Value 891.8m / Book Value Of Equity -138.8m)
Interest Expense / Debt = 0.08% (Interest Expense 81.8k / Debt 100.5m)
Taxrate = 21.0% (US default)
NOPAT = -99.7m (EBIT -99.7m, no tax applied on loss)
Current Ratio = 14.72 (Total Current Assets 101.6m / Total Current Liabilities 6.90m)
Debt / Equity = 3.98 (Debt 100.5m / last Quarter total Stockholder Equity 25.2m)
Debt / EBITDA = -1.02 (Net Debt 34.0m / EBITDA -98.8m)
Debt / FCF = -3.58 (Debt 100.5m / FCF TTM -28.1m)
Total Stockholder Equity = 38.6m (last 4 quarters mean)
RoA = -73.55% (Net Income -100.0m, Total Assets 135.9m )
RoE = -259.1% (Net Income TTM -100.0m / Total Stockholder Equity 38.6m)
RoCE = -72.17% (Ebit -99.7m / (Equity 38.6m + L.T.Debt 99.5m))
RoIC = -111.2% (set to none) (NOPAT -99.7m / Invested Capital 89.6m)
WACC = 12.57% (E(858.9m)/V(959.5m) * Re(14.03%)) + (D(100.5m)/V(959.5m) * Rd(0.08%) * (1-Tc(0.21)))
Shares Correlation 5-Years: 100.0 | Cagr: 23.53%
Discount Rate = 14.03% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -28.1m)
Revenue Correlation: 93.07 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: -143.6
EPS Correlation: -57.31 | EPS CAGR: -180.2%
EPS Growth-of-Growth: 2.73
Additional Sources for ASPI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle